- Dec Font Size
- Reset Text Size
- Inc Font Size
Geomatrix is a registered trademark of Jagotec AG. Shionogi Pharma’s use of the Geomatrix technology is under license from SkyePharma.
Low Dose SULAR (nisoldipine) Strengths for Individual Patient Hypertension Needs
Dear Healthcare Professional,
Shionogi Pharma, Inc. is pleased to announce the availability of SULAR with Geomatrix® Delivery System in the low dose strengths of 8.5mg, 17mg, 25.5mg, and 34mg - a once-a-day tablet proven to provide 24-hour control for hypertension.1
Hypertension is all about control and SULAR with Geomatrix delivery system assures you the confidence and control you are looking to provide for your patients.
Prescribe SULAR (nisoldipine) with Geomatrix Delivery System with Confidence
- Proven efficacy2
- Shown to blunt the rate of rise in early morning systolic blood pressure1*
- Established safety and tolerability profile
- SULAR with Geomatrix Delivery System does not have an AB rated generic equivalent…it is not substitutable
- Ensure your patients receive the SULAR you prescribe by writing 8.5mg, 17mg, 25.5mg, or 34mg
*Clinical significance unknown
Prescribe SULAR with Geomatrix Delivery System
Low dose strengths continue
to meet individual patient needs
Indication:
SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Important Safety Information:
The most common adverse events, reported in US placebo-controlled trials, were peripheral edema, headache, and dizziness. In rare cases, some patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration, and/or severity of
angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. Safety of SULAR in patients with heart failure has not been established. SULAR should be administered cautiously in patients over the age of 65 and in those with severe
hepatic dysfunction. Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of SULAR is recommended. SULAR should not be taken with grapefruit products.
Please click here for full prescribing information.
Your Healthcare Provider can give you more information about Sular or call (800) 849-9707 ext 1454. Ask your Healthcare Provider if Sular may be right for you.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Images are for illustrative purposes only.
References: 1. Punzi HA, Noveck R, Weiss RJ, et al. Are there differences in the effects of long-acting calcium antagonists on ambulatory blood pressure? Extended-release nisoldipine versus amlodipine as a model. Blood Press Monit. 1998;3:267-272. 2. Marazzi P. A study to demonstrate the equivalence in efficacy and safety of once-daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Acta Therapeutica. 1996;22:23-35.
